Interpreting the PISCES trial on fish oil in hemodialysis patients: lessons on trial design, biological exposure, and outcome measurement
Abstract
Patients receiving maintenance hemodialysis experience an exceptionally high cardiovascular risk, characterized by frequent recurrent events and a longstanding lack of effective preventive therapies. Most cardiovascular trials in this population have yielded neutral results, highlighting important limitations in both therapeutic strategies and outcome assessment. The PISCES trial recently reported significant reductions in both first and recurrent cardiovascular events with high-dose omega-3 fatty acids in patients undergoing hemodialysis, using a recurrent-event framework to capture overall cardiovascular burden. In this focused narrative review, we critically appraise the PISCES findings within the broader context of omega-3 research in chronic kidney disease and dialysis. Particular emphasis is placed on how biological exposure, population selection, and outcome frameworks influence the detectability of cardiovascular benefit in high-risk populations. PISCES challenges the prevailing notion that cardiovascular risk in hemodialysis is largely unmodifiable and underscores the importance of aligning therapeutic interventions with outcome measures that reflect total disease burden. More broadly, the trial illustrates how methodological choices may critically influence the interpretation of cardiovascular efficacy in populations with dense event clustering and high competing mortality.
Read the paper
Related studies
- eggNOG 5.0: a hierarchical, functionally and phylogenetically annotated orthology resource based on 5090 organisms and 2502 viruses
- Online Survival Analysis Software to Assess the Prognostic Value of Biomarkers Using Transcriptomic Data in Non-Small-Cell Lung Cancer
- OptiType: precision HLA typing from next-generation sequencing data
- Nicotinic Cholinergic System and COVID-19: In Silico Identification of an Interaction between SARS-CoV-2 and Nicotinic Receptors with Potential Therapeutic Targeting Implications
- Saccharomyces cerevisiae cells have three Omega class glutathione S-transferases acting as 1-Cys thiol transferases
- Hemolysis at low blood flow rates: in-vitro and in-silico evaluation of a centrifugal blood pump
Go deeper in Evidence Hub
Evidence Hub adds a study data sheet (design, sample size, evidence level, key numbers), an AI summary and a chat grounded in the paper's text.